| Dr Syed Ali Akbar Jafery, MD | |
|
63 Main St, Brockton, MA 02301-4042 | |
| (508) 559-6699 | |
| (508) 559-5073 |
| Full Name | Dr Syed Ali Akbar Jafery |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 63 Main St, Brockton, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255582698 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 232777 (Massachusetts) | Primary |
| Entity Name | Uhs Of Westwood Pembroke Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760453328 PECOS PAC ID: 6204740947 Enrollment ID: O20031117000702 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
| Entity Name | Boston University Psychiatry Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073619854 PECOS PAC ID: 7911805361 Enrollment ID: O20031223000346 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
| Entity Name | Nova Psychiatric Services, P.c |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881782522 PECOS PAC ID: 4183524887 Enrollment ID: O20040109000776 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
| Entity Name | Child & Family Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205813540 PECOS PAC ID: 9234116583 Enrollment ID: O20040812000815 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
| Entity Name | Southcoast Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336137629 PECOS PAC ID: 0749171957 Enrollment ID: O20040920000138 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
| Entity Name | Southcoast Hospitals Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306871223 PECOS PAC ID: 1850282310 Enrollment ID: O20041214000621 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
| Entity Name | Edinburg Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073617353 PECOS PAC ID: 4486681087 Enrollment ID: O20060503000404 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
| Entity Name | Starr Psychiatric Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871687129 PECOS PAC ID: 4385742626 Enrollment ID: O20070609000089 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
| Entity Name | Oasis Behavioral Health Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639436918 PECOS PAC ID: 8426485251 Enrollment ID: O20200217002627 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Syed Ali Akbar Jafery, MD 63 Main St, Brockton, MA 02301-4042 Ph: (508) 559-6699 | Dr Syed Ali Akbar Jafery, MD 63 Main St, Brockton, MA 02301-4042 Ph: (508) 559-6699 |
News Archive
Supporters of controversial legislation to give state regulators power to approve, deny or modify changes in health insurance rates have returned from their summer recess to find added opposition as they push for its passage before the session wraps up. Gov. Jerry Brown's finance officials came out against Assembly Bill 52 at a Senate Appropriations Committee hearing this week, raising concerns about the costs of the rate-regulation proposal.
To share its expertise in medical device manufacturing, global engineering technologies company Renishaw is returning to RAPID + TCT, the leading additive manufacturing and 3D printing event in the United States.
The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.
In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.
› Verified 4 days ago
Demin Ma, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 680 Centre St, Brockton, MA 02302 Phone: 508-941-7228 Fax: 508-941-6401 | |
Dr. Sharon M Parnes, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 830 Oak St Ste 220e, Brockton, MA 02301 Phone: 508-427-3870 Fax: 617-508-5063 | |
Dr. Sarah Yasmin, M.D., M.P.H Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 940 Belmont Street (116a), Vabhs Mental Health Service, Brockton, MA 02301 Phone: 774-826-2476 Fax: 774-826-3129 | |
Dil Tahera, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 940 Belmont St, Brockton, MA 02301 Phone: 774-826-3151 | |
Anne Ling Li, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 165 Quincy St, Brockton, MA 02302 Phone: 508-897-2000 Fax: 508-897-2223 | |
Elena B Nikolskaia, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 940 Belmont Street, Brockton Va Medical Center, Brockton, MA 02401 Phone: 617-971-3018 | |
Dr. Olga Osokina, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 940 Belmont St, Brockton, MA 02301 Phone: 774-826-2326 |